Meeting
2014 ASCO Quality Care Symposium
Treatment, mortality, and health care costs in a U.S. cohort of indolent non-Hodgkin lymphoma patients with relapsed or refractory disease.
Authors
Nicole Meyer
Truven Health Analytics, Inc., Cambridge, MA
Nicole Meyer, Xue Song, Stephanie A. Gregory, Scott David Ramsey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Science of Quality and Cost, Value, and Policy in Quality
Track
Science of Quality,Cost, Value, and Policy in Quality
Sub Track
Measuring Value and Costs
Citation
J Clin Oncol 32, 2014 (suppl 30; abstr 35)
DOI
10.1200/jco.2014.32.30_suppl.35
Abstract #
35
Poster Bd #
B21
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.
First Author: Carrie Ho
Poster
2022 ASCO Annual Meeting
First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update.
First Author: Lorenzo Falchi
Poster
2018 ASCO Annual Meeting
Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.
First Author: He Huang
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin